Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05390853
Other study ID # CE AVEC_96-2022-SPER-AUSLIM
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 24, 2023
Est. completion date November 2024

Study information

Verified date June 2023
Source Montecatone Rehabilitation Institute S.p.A.
Contact Silvia Olivi, MD
Phone +39 0542 632811
Email silvia.olivi@montecatone.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Spinal Cord Injury (SCI) at the cervical level results in motor and sensory impairment below the lesion level and may determine a consistent loss of the use of the upper limbs, with a substantial impact on daily life activities. Therefore, functionality recovery of the upper limbs, of the hands in particular, represents a priority rehabilitation target. Studies in the literature show that the most relevant recovery occurs in the first months after SCI and that neuromodulation techniques may facilitate it. Transcranial Direct Current Stimulation (tDCS ) is a non-invasive neuromodulation technique. The present pilot, randomized controlled study aims at exploring the feasibility and efficacy of an early application of tDCS, in addition to the traditional physiotherapy treatment for the functional recovery of the upper limb, in incomplete traumatic tetraplegic subjects in the sub-acute phase after SCI occurrence. Patients hospitalized at the Montecatone Rehabilitation Institute are randomly assigned to Active tDCS or Sham tDCS.


Description:

Spinal Cord Injury (SCI) at the cervical level results in motor and sensory impairment below the lesion level and may determine a consistent loss of the use of the upper limbs, with a substantial impact on daily life activities. Therefore, functionality recovery of upper limbs, of the hands in particular, represents a priority rehabilitation target. In cases of incomplete tetraplegia, the main rehabilitation goal is the recovery of the maximum functional capacity, in order to improve autonomy or, in the most serious cases, avoid complications due to immobilization. Studies in the literature show that the most relevant recovery occurs in the first months after SCI and that neuromodulation techniques may facilitate it. Transcranial Direct Current Stimulation (tDCS ) is a non-invasive neuromodulation technique capable of modifying cortical excitability through direct, low intensity current, generated by a programmable medical device and delivered through electrodes placed on the scalp. Some authors have explored its potential role in facilitating functional recovery and treating spasticity in SCI subjects, however there are few studies on the use of neuromodulation induced by tDCS as an aid for the functional recovery of upper limbs in tetraplegic subjects. Moreover, most of such studies are on chronic SCI persons only. The present pilot, randomized controlled study aims at exploring the feasibility and efficacy of an early application of tDCS, in the sub-acute phase after SCI occurrence, for the functional recovery of the upper limb, in addition to the traditional physiotherapy treatment, in incomplete traumatic tetraplegic patients, hospitalized at the Montecatone Rehabilitation Institute. They are randomly assigned to Active tDCS (A) or Sham tDCS (S) (parallel arms design,1:1 allocation ratio). Two tDCS daily sessions for 5 days a week, for 2 consecutive weeks, are carried out simultaneously with the usual rehabilitation treatment of the upper limb, that is administered also at least 4 weeks before and 4 weeks after the tDCS treatment period. Most outcomes are measured up to 4 weeks after the completion of the tDCS treatment period.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria: - Traumatic SCI; - SCI neurological level, according to the American Spinal Injury Association (ASIA) definitions, from C3 to C7, included; - incomplete SCI (i.e. ASIA Impairment Scale: B, C or D); - distance from the SCI event: from 3 to 6 months; - residual motor ability of the target upper limb; - stable clinical conditions; - tolerance to sitting position for at least 45 minutes; - subjects capable and collaborating, able to give informed consent in person. Exclusion Criteria: - presence of implanted devices (e.g. pacemakers, intrathecal infusers, neurostimulators, hearing aids); - positive history of brain lesions; - presence of cerebral metallic implants (clips) or intracranial implants (e.g. ventriculoperitoneal shunt); - history of epilepsy or previous state of epileptic disease; - mechanical ventilation in place; - history of psychotic disorders; - history of severe neurodegenerative disease; - concomitant pre-existing clinical conditions that may interfere with movements of the target arm or hand (e.g. severe osteoarthritis, joint injuries, plexus injuries, peripheral nerve injuries, partial amputations); - use of antiepileptic drugs blocking Sodium o Calcium channels (e.g. Carbamazepine) or N-Methyl-D-Aspartate receptor antagonists (e.g. Dextromethorphan); - history of drugs abuse; - further contraindications to the use of TMS for PEMs elicitation (e.g. migraine with aura, permanent head / face tattoos); - presence of brain tumor; - pregnancy in progress.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Active tDCS
tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode. Active stimulation is carried out with a current intensity of 2 milliAmpere. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes. During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb. In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.
Sham tDCS
tDCS application is anodic, in the M1 area (Primary Motor Cortex) right or left, contralateral to the pre-defined target limb. The cathode is positioned in the supraorbital area, contralateral to the anode. Sham stimulation is carried out through a dedicated program, which increases the current for several seconds up to the target intensity and then decreases it gradually in a few seconds, so that subjects experience the same itching and tingling experience as in active stimulation, but they do not receive any significant therapeutic currents. Each tDCS session lasts 20 minutes. tDCS is administered simultaneously during the first 20 minutes of the usual upper limb rehabilitation physiotherapy, which will continue for a further 20 minutes. During the whole study period (10 weeks) each patient is not subjected to any focal treatments in the target upper limb. In the study period, the contralateral limb is rehabilitated and evaluated according to usual practice.

Locations

Country Name City State
Italy Montecatone Rehabilitation Institute S.p.A. Imola BO

Sponsors (1)

Lead Sponsor Collaborator
Montecatone Rehabilitation Institute S.p.A.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in motor function, after the tDCS treatment period completion Motor function (i.e. muscle strength) of the target upper limb, determined according to the Medical Research Council /International Classification for the Surgery of the Tetraplegic Hand (MRC/ICSTH) Baseline 1 (initial visit); Baseline 2 (second visit, 2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1)
Secondary Permanence of motor function, 4 weeks after the tDCS treatment period completion Motor function (i.e. muscle strength) of the target upper limb, determined according to the Medical Research Council /International Classification for the Surgery of the Tetraplegic Hand (MRC/ICSTH) Just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Secondary Change in strength, sensitivity and grip, up to 4 weeks after the tDCS treatment period completion Strength, sensitivity and grip of the target upper limb, determined according to the Graded Redefined Assessment of Strength Sensibility and Prehension (GRASSP) Baseline 1 (initial visit); Baseline 2 (second visit, 2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Secondary Change in spasticity, up to 4 weeks after the tDCS treatment period completion Spasticity of the target upper limb, determined according to the Modified Ashworth Scale (MAS) Baseline 1 (initial visit); Baseline 2 (second visit, 2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Secondary Change in motor function and muscle activity during rest activity, from the beginning of the tDCS treatment period until 4 weeks after its completion Motor function and muscle activity during rest activity, determined through Neurographic assessment of the following muscles: deltoid, biceps, carpus extensor, thumb abductor brevis just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Secondary Change in Motor Evoked Potentials, from the beginning of the tDCS treatment period until 4 weeks after its completion Motor Evoked Potentials (PEMs), elicited by Transcranial Magnetic Stimulation (TMS), of the following muscles: deltoid, biceps, carpus extensor, thumb abductor brevis just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1)
Secondary Pain, up to 4 weeks after the tDCS treatment period completion Pain assessment in the target upper limb, determined according to the Numeric Rating Scale (NRS) Baseline 1 (initial visit); Baseline 2 (2 weeks after Baseline 1); just before tDCS session n.1 (4 weeks after Baseline 1); just after tDCS session n.20 (6 weeks after Baseline 1); 4 weeks after tDCS session n.20 (10 weeks after Baseline 1
Secondary Safety of the tDCS treatment Incidence of adverse events related to the tDCS treatments During and after each tDCS session (from week 4 to week 6 after Baseline 1); in the 4 weeks after tDCS session n.20 (up to 10 weeks after Baseline 1)
Secondary Tolerability of the tDCS treatment Subjective patient's perception of the fatigue of the treatments with tDCS associated with the usual rehabilitation physiotherapy treatment of the upper limb, evaluated through a short in-house developed questionnaire Just after tDCS session n.20 (week 6 after Baseline 1)
See also
  Status Clinical Trial Phase
Recruiting NCT03680872 - Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System N/A
Not yet recruiting NCT06437548 - Epidural Stimulation for Upper Extremity Function N/A
Completed NCT03385005 - Evaluating Neuromuscular Stimulation for Restoring Hand Movements Early Phase 1
Completed NCT05054803 - Cell Therapy for Chronic Traumatic Cervical Incomplete Spinal Cord Injury Phase 1/Phase 2
Recruiting NCT02983955 - UPNRIDE Powered Wheelchair for Individuals With Walking Impairment: Evaluation of Safety and Usability N/A
Recruiting NCT03048331 - Functional Electrical Stimulation (FES) and Reconstructive Tetraplegia Hand and Arm Surgery N/A
Not yet recruiting NCT04465825 - Developing Strategies to Optimize the Exercise Response After Tetraplegia. N/A
Completed NCT04383873 - Effectiveness Analysis of Armeo Spring Device as a Rehabilitation Treatment in Spinal Cord Injured Patients N/A
Active, not recruiting NCT05462925 - Prediction of Muscle Responsiveness to FES Therapy N/A
Completed NCT04523636 - Evaluation of Splinting in Tetraplegia N/A
Recruiting NCT04276181 - Combined Nerve and Tendon Transfer for the Restoration of Hand Function in Individuals With Tetraplegia
Recruiting NCT04641793 - BoMI for Muscle Control N/A
Recruiting NCT05863754 - Grasp-Release Assessment of a Networked Neuroprosthesis Device N/A
Withdrawn NCT04142814 - Randomized Controlled Study on T-PEP Versus IPV Method for Lower Respiratory Airways Clearance in Tetraplegic Tracheotomized Spinal Cord Injured Patients N/A
Active, not recruiting NCT03184792 - Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury N/A
Recruiting NCT02329652 - Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury N/A
Enrolling by invitation NCT04369131 - Controlling Orthostatic Hypotension in People With Cervical Spinal Cord Injury N/A
Completed NCT06159946 - Access-H20 Faucet for Spinal Cord Injury N/A
Completed NCT03239301 - Robotic-assisted Upper Extremity Training in Spinal Cord Injury Patients N/A
Completed NCT05362422 - PAS for Post-SCI Neuropathic Pain N/A